SG163540A1 - Substituted glycinamides having an antithrombotic and factor xa- inhibiting effect - Google Patents

Substituted glycinamides having an antithrombotic and factor xa- inhibiting effect

Info

Publication number
SG163540A1
SG163540A1 SG201004677-9A SG2010046779A SG163540A1 SG 163540 A1 SG163540 A1 SG 163540A1 SG 2010046779 A SG2010046779 A SG 2010046779A SG 163540 A1 SG163540 A1 SG 163540A1
Authority
SG
Singapore
Prior art keywords
antithrombotic
factor
inhibiting effect
substituted glycinamides
glycinamides
Prior art date
Application number
SG201004677-9A
Other languages
English (en)
Inventor
Henning Priepke
Georg Dahmann
Kai Gerlach
Roland Pfau
Wolfgang Wienen
Annette Schuler-Metz
Sandra Handschuh
Herbert Nar
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of SG163540A1 publication Critical patent/SG163540A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
SG201004677-9A 2005-06-30 2006-06-28 Substituted glycinamides having an antithrombotic and factor xa- inhibiting effect SG163540A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05014270 2005-06-30

Publications (1)

Publication Number Publication Date
SG163540A1 true SG163540A1 (en) 2010-08-30

Family

ID=35907001

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201004677-9A SG163540A1 (en) 2005-06-30 2006-06-28 Substituted glycinamides having an antithrombotic and factor xa- inhibiting effect

Country Status (33)

Country Link
US (3) US20100216769A1 (es)
EP (1) EP1899330B9 (es)
JP (1) JP4768016B2 (es)
KR (1) KR101321722B1 (es)
CN (1) CN101213195B (es)
AR (1) AR054627A1 (es)
AT (1) ATE489381T1 (es)
AU (1) AU2006265216B2 (es)
BR (1) BRPI0612580A8 (es)
CA (1) CA2613059C (es)
CY (1) CY1111627T1 (es)
DE (1) DE502006008392D1 (es)
DK (1) DK1899330T3 (es)
EA (1) EA015188B1 (es)
EC (1) ECSP078058A (es)
ES (1) ES2357029T3 (es)
HK (1) HK1116190A1 (es)
HR (1) HRP20110044T2 (es)
IL (1) IL188323A (es)
MX (1) MX2007016253A (es)
MY (1) MY145883A (es)
NO (1) NO340670B1 (es)
NZ (1) NZ565440A (es)
PE (1) PE20070171A1 (es)
PL (1) PL1899330T3 (es)
PT (1) PT1899330E (es)
RS (1) RS51572B (es)
SG (1) SG163540A1 (es)
SI (1) SI1899330T1 (es)
TW (1) TWI392495B (es)
UA (1) UA94910C2 (es)
WO (1) WO2007003536A1 (es)
ZA (1) ZA200708525B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1799684B1 (en) 2004-10-04 2014-12-03 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
JP2009543812A (ja) * 2006-07-20 2009-12-10 キャスケイド・セラピューティクス・インコーポレイテッド 5−HT2Cリガンドとしてのテトラヒドロ−5H−ピリド[2,3−d]アゼピン
PE20081834A1 (es) * 2006-12-31 2009-01-16 Boehringer Ingelheim Int Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos
EP1975165A1 (de) 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel
WO2009063028A2 (en) * 2007-11-15 2009-05-22 Boehringer Ingelheim International Gmbh Substituted amides, manufacturing and use thereof as medicaments
JP5562865B2 (ja) 2007-12-17 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Trpv1のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター
JP5684719B2 (ja) 2008-12-05 2015-03-18 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Plk阻害剤としての5,7−ジヒドロ−6h−ピリミド[5、−4d][1]ベンゾアゼピン−6−チオン
EP2398781A1 (en) * 2009-02-17 2011-12-28 Msd K.K. 1,4-benzodiazepin-2-on derivatives
KR20130075732A (ko) 2010-03-30 2013-07-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
ES2953393T3 (es) 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
BR112015014482A2 (pt) 2012-12-18 2017-11-21 Icahn School Med Mount Sinai vacinas para vírus influenza e seus usos
FI3102200T3 (fi) * 2014-02-07 2023-05-31 Exithera Pharmaceuticals Inc Terapeuttisia yhdisteitä ja koostumuksia
CN105622511B (zh) * 2014-11-03 2018-01-23 北京瑞都医药科技有限公司 一种减肥药物及其制备方法
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
WO2020007902A1 (en) 2018-07-05 2020-01-09 Bayer Aktiengesellschaft Substituted thiophenecarboxamides and analogues as antibacterials agents
CN111196772B (zh) * 2018-11-16 2022-09-30 沈阳化工研究院有限公司 一种芳酰氨基异丁酰衍生物及其应用
BR112022010333A2 (pt) 2019-12-20 2022-08-16 Bayer Ag Tieniloxazolonas e análogos
EP4240348A1 (en) 2020-11-06 2023-09-13 Boehringer Ingelheim International GmbH 2-[thiophen-2-yl)formamido]-n-(phenyl)-2-methylpropanamide derivatives and the use thereof as medicament

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855715B1 (en) 1999-06-14 2005-02-15 Eli Lilly And Company Serine protease inhibitors
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
EA005893B1 (ru) 2000-03-21 2005-06-30 Смитклайн Бичам Корпорейшн Ингибиторы протеаз
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
WO2002092563A2 (en) 2001-05-17 2002-11-21 Smithkline Beecham Corporation Protease inhibitors
JP2004300133A (ja) * 2002-11-19 2004-10-28 Takeda Chem Ind Ltd アミン誘導体
AU2003280838A1 (en) 2002-11-19 2004-06-15 Takeda Pharmaceutical Company Limited Indole derivatives as somatostatin agonists or antagonists
DE10254336A1 (de) * 2002-11-21 2004-06-03 Merck Patent Gmbh Carbonsäureamide
US7250415B2 (en) 2003-06-04 2007-07-31 Bristol-Myers Squibb Company 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors
KR20070012552A (ko) * 2004-05-13 2007-01-25 베링거 인겔하임 인터내셔날 게엠베하 신규한 치환된 티오펜카복스아미드, 이의 제조방법 및약제로서의 이의 용도
EP1748996A1 (de) 2004-05-13 2007-02-07 Boehringer Ingelheim International GmbH Substituierte thiophencarbonsäureamide, deren herstellung und deren verwendung als arzneimittel
WO2005111013A1 (de) 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Substituierte thiophen-2-carbonsäureamide, deren herstellung und deren verwendung als arzneimittel
DE102004047840A1 (de) 2004-09-29 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Thiophencarbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
PE20081834A1 (es) 2006-12-31 2009-01-16 Boehringer Ingelheim Int Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos

Also Published As

Publication number Publication date
EA015188B1 (ru) 2011-06-30
MY145883A (en) 2012-05-15
ES2357029T3 (es) 2011-04-15
NO20075186L (no) 2008-02-14
EP1899330A1 (de) 2008-03-19
US9062034B2 (en) 2015-06-23
RS51572B (en) 2011-08-31
KR101321722B1 (ko) 2013-10-25
BRPI0612580A8 (pt) 2017-12-26
TWI392495B (zh) 2013-04-11
TW200738692A (en) 2007-10-16
NZ565440A (en) 2011-04-29
PT1899330E (pt) 2011-01-11
ZA200708525B (en) 2009-08-26
AU2006265216B2 (en) 2011-09-29
KR20080033318A (ko) 2008-04-16
US9676781B2 (en) 2017-06-13
CN101213195B (zh) 2012-05-09
BRPI0612580A2 (pt) 2010-11-23
EA200702620A1 (ru) 2008-06-30
NO340670B1 (no) 2017-05-29
AU2006265216A1 (en) 2007-01-11
US20100216769A1 (en) 2010-08-26
EP1899330B9 (de) 2011-11-09
CY1111627T1 (el) 2015-10-07
WO2007003536A1 (de) 2007-01-11
CA2613059A1 (en) 2007-01-11
PL1899330T3 (pl) 2011-05-31
EP1899330B1 (de) 2010-11-24
DE502006008392D1 (de) 2011-01-05
US20150252050A1 (en) 2015-09-10
MX2007016253A (es) 2008-03-07
SI1899330T1 (sl) 2011-03-31
HRP20110044T1 (en) 2011-02-28
JP4768016B2 (ja) 2011-09-07
DK1899330T3 (da) 2011-02-21
JP2008546741A (ja) 2008-12-25
AR054627A1 (es) 2007-07-04
HRP20110044T2 (hr) 2012-02-29
PE20070171A1 (es) 2007-03-08
CA2613059C (en) 2013-12-24
IL188323A (en) 2013-08-29
ECSP078058A (es) 2008-01-23
IL188323A0 (en) 2008-04-13
CN101213195A (zh) 2008-07-02
ATE489381T1 (de) 2010-12-15
UA94910C2 (ru) 2011-06-25
US20130184256A1 (en) 2013-07-18
HK1116190A1 (en) 2008-12-19

Similar Documents

Publication Publication Date Title
SG163540A1 (en) Substituted glycinamides having an antithrombotic and factor xa- inhibiting effect
MY146623A (en) Substituted prolinamides, manufacturing, and the use thereof as medicaments
TW200602033A (en) New carboxylic acid amides, the preparation thereof and their use as medicaments
WO2009065919A3 (de) Organische verbindungen
WO2009065920A3 (de) Verbindungen
WO2005103037A3 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
WO2007036532A3 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
TW200504032A (en) New carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions
UA91854C2 (ru) Фунгицидная комбинация действующих веществ
TW200504067A (en) New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
SG169337A1 (en) Aryl sulfonamides with an analgesic action
NO20070089L (no) DPP-IV inhibitorer
WO2009065922A3 (de) Organische verbindungen
TW200604178A (en) New substituted thiophene carboxamides, process for their preparation and their use as medicaments
TW200700358A (en) Organic compounds
TW200738693A (en) Substituted biaryls, process for their manufacture and use thereof as medicaments
TW200722424A (en) Substituted piperidines
UA88956C2 (ru) Синергическая фунгицидная комбинация действующих веществ
MX2010003849A (es) Antagonistas de cgrp.
WO2007020261A3 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
WO2006034822A8 (de) Neue substituierte thiophencarbonsäureamide, deren herstellung und deren verwendung als arzneimittel
MY148769A (en) Process for the synthesis of derivatives of 3-amino-tetrahydrofuran-3-carboxylic acid and use thereof as medicaments
TN2010000072A1 (en) New compounds
WO2009034029A3 (de) 1-substituierte 4 -heterocyclylpiperidine als cgrp antagonisten
TW200740798A (en) Substituted amides, process for their manufacture and use thereof as medicaments